An immune and cancer cell-targeting antibody therapy has shown potential to eradicate residual traces of deadly blood cell cancer, multiple myeloma, according to interim results from a clinical trial. 

The trial included 18 patients who underwent up to six cycles of treatment with the antibody linvoseltamab. On highly sensitive tests, none of the patients had detectable disease, revealed the study presented at the American Society of Hematology (ASH) annual meeting in Orlando, US.